Axsome Beats Securities Suit Over Migraine Drug, For Now

By Henrik Nilsson · September 26, 2023, 7:53 PM EDT

A New York federal judge on Monday tossed a proposed securities class action alleging that biopharmaceutical company Axsome hid issues about its migraine drug, leading to a significant stock price drop,...

To view the full article, register now.

Documents

Case Information

Case Title

In re Axsome Therapeutics, Inc. Securities Litigation

Case Number

1:22-cv-03925

Court

New York Southern

Nature of Suit

Securities/Commodities

Date Filed

May 13, 2022